Upload File

first response: nsclc highlights from chicago

18

Upload: orinda

Post on 14-Feb-2016

49 views

Category:

Documents


0 download

Report

Tags:

DESCRIPTION

First Response: NSCLC Highlights From Chicago. RTOG 0617 Overall Survival Results. ALK Rearrangement Positive Advanced NSCLC. MPDL3280A Phase Ia: Response by PD-L1 IHC Status. GALAXY-1 Overall Survival: Adenocarcinoma. LUME Lung 1: Overall Survival Adenocarcinoma. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: First Response: NSCLC Highlights From Chicago
Page 2: First Response: NSCLC Highlights From Chicago
Page 3: First Response: NSCLC Highlights From Chicago
Page 4: First Response: NSCLC Highlights From Chicago
Page 5: First Response: NSCLC Highlights From Chicago
Page 6: First Response: NSCLC Highlights From Chicago
Page 7: First Response: NSCLC Highlights From Chicago
Page 8: First Response: NSCLC Highlights From Chicago
Page 9: First Response: NSCLC Highlights From Chicago
Page 10: First Response: NSCLC Highlights From Chicago
Page 11: First Response: NSCLC Highlights From Chicago
Page 12: First Response: NSCLC Highlights From Chicago
Page 13: First Response: NSCLC Highlights From Chicago
Page 14: First Response: NSCLC Highlights From Chicago
Page 15: First Response: NSCLC Highlights From Chicago
Page 16: First Response: NSCLC Highlights From Chicago
Page 17: First Response: NSCLC Highlights From Chicago
Page 18: First Response: NSCLC Highlights From Chicago

HIGHLIGHTS OF PRESCRIBING INFORMATION When … · Non-Small Cell Lung Cancer (NSCLC) •in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment

Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

NSCLC: Targeted Therapies and Beyond · approved for the treatment of NSCLC. There are also drugs that target specific NSCLC–associated mutations. For example, 10-35 percent of

CHICAGO CHAPTER ICRI · 2017. 2. 20. · ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter April Dinner 11 Meeting Highlights 5th Annual Chicago Chapter

PANERA BREAD (Corporate|Chicago MSA) 5500 West Touhy ... Bread - Skokie, IL - OM.pdfINVESTMENT HIGHLIGHTS: INVESTMENT HIGHLIGHTS • Located within the Chicago MSA • New construction

NSCLC - InOncology · 2020-06-15 · NSCLC, the most common type of lung cancer, is genomically diverse ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC,

Tratamiento TKI-estudio IFUM NSCLC

5 조 NSCLC

Year in Review: Therapeutic Advances in Treating …...– ASCO Chicago 2017 – ESMO Madrid 2017 – WCLC Japan 2017 Outline 3 Molecular Classification of NSCLC: 2017 Rosell and Karachaliou

grad do highlights - University of Chicago · Roosevelt University University of Illinois at Chicago

NSCLC dengan bronkoskopi

Mlm nsclc prevencion_oportuno_2016_b

Improving Outcomes in Advanced NSCLC with Immune ...•5-year survival rate is 19% (NSCLC + SCLC) •From 2009–2015, the relative survival rate for NSCLC was 25% •Recent overall

PERMIT APPLICATION PROCESS HIGHLIGHTS - Chicago Park …€¦ · SPECIAL EVENT PERMIT APPLICATION. CHICAGO PARK DISTRICT. FEE AND DOCUMENT DEADLINE (see page 18 for event levels)

1 ACR 2011 Medical Passport Highlights of ACR 2011 Chicago, IL November 2011

Nsclc slide deck

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%

Surgical Approach to NSCLC

Drugs to treat nsclc

Lungenkarzinom Nicht Kleinzellig Nsclc A

Immunotherapy in NSCLC

Concurrent ChemoRT in NSCLC

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

Nsclc 2nd line

THE UNIVERSITY OF CHICAGO PRESS Highlights for Fall 2019

ZIRKULIERENDE MICRO-RNA IN NSCLC | NSCLC-TAG ST. GALLEN | 5/1/2014 Zirkulierende micro-RNA in Patienten mit NSCLC PD Dr. med. et rer. nat. M. Joerger Medizinische

HIGHLIGHTS OF PRESCRIBING INFORMATION2.1 Patient Selection for EGFR Mutation-Positive Metastatic NSCLC 2.2 Recommended Dose 2.3 Dose Modifications for Adverse Reactions 2.4 Dose Modifications

Second line therapy for nsclc

Immune therapy in NSCLC

CCO Metastatic NSCLC Slides

nonsquamous NSCLC

protokol KOC FNHK NSCLC 2020

Gevolgen van PATH project voor NSCLC - Zorg … van PATH project voor NSCLC Hoe tillen we Moleculaire Diagnostiek van NSCLC naar hoger plan ? Ed Schuuring KMBP (Klinisch Moleculair

Highlights in NSCLC From the American Society of Clinical Oncology

CHICAGO CHAPTER ICRI · Crack Repair Announcment ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter September Dinner 11 Meeting Highlights ... On December